search
Back to results

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Primary Purpose

B-Cell Malignancies

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Parsaclisib
parsaclisib + itacitinib
parsaclisib + ruxolitinib
parsaclisib + ibrutinib
Sponsored by
Incyte Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for B-Cell Malignancies focused on measuring non-Hodgkin lymphoma, phosphatidylinositol 3-kinase, myeloproliferative neoplasm

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib.
  • Currently tolerating treatment in the parent Protocol.
  • Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator.
  • Has at least stable disease, as determined by the investigator.
  • Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
  • Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol.
  • Willingness to avoid pregnancy or fathering children
  • Ability to comprehend and willingness to sign an ICF

Exclusion Criteria:

  • Has been permanently discontinued from study treatment in the parent Protocol for any reason.
  • Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study.
  • Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
  • Pregnant or breastfeeding women.

Sites / Locations

  • Uab Comprehensive Cancer CenterRecruiting
  • University of Alabama At BirminghamRecruiting
  • Mayo Clinic Rochester
  • University of Arizona Cancer Center-Out Pt.
  • City of Hope National Medical Center
  • California Cancer Associates For Research and Excellence
  • Innovative Clinical Research InstituteRecruiting
  • Rocky Mountain Cancer CenterRecruiting
  • Rush University Medical Center-Consultants in HematologyRecruiting
  • University of Kansas Hospital AuthorityRecruiting
  • Rcca Md, Llc
  • Massachusetts General HospitalRecruiting
  • University of Michigan Cancer CenterRecruiting
  • University of Michigan Health SystemRecruiting
  • Hattiesburg Clinic HematologyRecruiting
  • Saint Luke'S Hospital of Kansas CityRecruiting
  • Hca Midwest Health-Research Medical CenterRecruiting
  • Comprehensive Cancer Centers of NevadaRecruiting
  • Roswell Park Cancer InstituteRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Duke University Medical Center
  • University Hospitals Case Medical CenterRecruiting
  • Cleveland Clinic
  • The Ohio State University
  • Knight Cancer Institute At Oregon Health and Science UniversityRecruiting
  • Baylor Scott White Univeristy Medical CenterRecruiting
  • University of Washington-Seattle Cancer Care AllianceRecruiting
  • Medical University of Vienna
  • Cliniques Universitaires Ucl Saint-LucRecruiting
  • Universitair Ziekenhuis Gent
  • Universitaire Ziekenhuis Leuven - Gasthuisberg
  • University Hospital Hradec Kralove
  • Univerzita Karlova V Praze 1. Lekarska Fakulta
  • University Hospital Kralovkse Vinohrady
  • Fakultni Nemocnice V Motole
  • The Finsen Centre National HospitalRecruiting
  • Sjaellands Universitets Hospital RoskildeRecruiting
  • Aarhus University Hospital
  • Centre Antoine LacassagneRecruiting
  • Ap-Hp Groupe Hospitalier Saint-Louis Lariboisiere Fernand-Widal Site Saint Louis (Paris)
  • Hospital Universitaire Pitie-SalpetriereRecruiting
  • Centre Hospitalier Universitaire de Toulouse
  • Chru Hopitaux de Tours Hospital Bretonneau
  • Petz Aladar County Teaching Hospital
  • Hadassah Hebrew University Medical Center Ein Karem HadassahRecruiting
  • Rabin Medical Center - Beilinson HospitalRecruiting
  • Sheba Medical Center
  • University of Bologna Institute of Haematology L E A Seragnoli
  • Lstituto Di Ematologia Lorenzo Ea.Seragnoli Universita Degli Studi Di Bologna - Policlinico S. Or
  • Azienda Ospedaliero-Universitaria Careggi (Aouc)
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori
  • Fondazione Irccs Ca Granda Ospedale Maggiore
  • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
  • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
  • Universita Di Napoli Federico Ii
  • Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
  • Azienda Ospedaliero Universitaria PisanaRecruiting
  • Ospedale Santa Maria Delle CrociRecruiting
  • Ospedale Sant. Eugenio
  • Juntendo University Hospital
  • National Cancer Center Hospital
  • Kansai Medical University Hospital
  • Tokai University HospitalRecruiting
  • Kobe City Medical Center General HospitalRecruiting
  • University Hospital Kyoto Prefectural University of MedicineRecruiting
  • Nho Matsumoto Medical CenterRecruiting
  • Miyagi Cancer CenterRecruiting
  • Jrc Aichi Medical Center Nagoya Daini HospitalRecruiting
  • Niigata Cancer Center Hospital
  • Osaka Metropolitan University HospitalRecruiting
  • Hokuyukai Sapporo Hokuyu HospitalRecruiting
  • National Hospital Org. Hokkaido Cancer Center
  • Tohoku University HospitalRecruiting
  • Tokyo Medical University HospitalRecruiting
  • Tenri HospitalRecruiting
  • Nippon Medical School HospitalRecruiting
  • Yokohama Municipal Citizens HospitalRecruiting
  • University of Fukui HospitalRecruiting
  • The Catholic University of Korea Seoul St. Mary'S Hospital
  • Haukeland University Hospital
  • Sp Zoz Szpital Uniwersytecki
  • Wwcoit Im. M. Kopernika W Lodzi
  • Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
  • Hospital General Unviersitario de Alicante
  • Ico Hospital Germans Trias I PujolRecruiting
  • Hospital Del Mar
  • Hospital Clinic Barcelona
  • Hospital Clinic I ProvincialRecruiting
  • Hospital General Universitario Gregorio MaranonRecruiting
  • Hospital Universitario Fundacin Jimnez Daz
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario Hm Sanchinarro
  • Hospital Universitario Quironsalud MadridRecruiting
  • Hospital Universitario Virgen Del Rocio
  • Karolinska University Hospital Solna
  • Istanbul Medipol Universitesi Ibagcilar Medipol Mega Universitesi Hastanesi
  • Ege University Hospital
  • Birmingham Heartlands Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

parsaclisib

parsaclicib + itacitinib

parsaclisib + ruxolitinib

parsaclisib + ibrutinib

Arm Description

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Number of participants with treatment-related AEs

Secondary Outcome Measures

Full Information

First Posted
August 10, 2020
Last Updated
October 3, 2023
Sponsor
Incyte Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT04509700
Brief Title
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Official Title
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 3, 2020 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
Detailed Description
The purpose of this study is to provide continued use of parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib to participants who are currently enrolled in an Incyte-sponsored study and receiving the same treatment, who have at least stable disease, who are obtaining clinical benefit (in the opinion of the investigator) on the current study treatment, as defined by the parent Protocol, and who are unable to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib outside a clinical study. Participants will continue on the same dose and schedule as the ones being administered in the Incyte-sponsored parent Protocol at the time of the rollover. The study will collect and assess safety information with regards to AEs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
B-Cell Malignancies
Keywords
non-Hodgkin lymphoma, phosphatidylinositol 3-kinase, myeloproliferative neoplasm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
parsaclisib
Arm Type
Experimental
Arm Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Arm Title
parsaclicib + itacitinib
Arm Type
Experimental
Arm Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
Arm Title
parsaclisib + ruxolitinib
Arm Type
Experimental
Arm Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
Arm Title
parsaclisib + ibrutinib
Arm Type
Experimental
Arm Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Intervention Type
Drug
Intervention Name(s)
Parsaclisib
Other Intervention Name(s)
INCB050465
Intervention Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Intervention Type
Drug
Intervention Name(s)
parsaclisib + itacitinib
Other Intervention Name(s)
INCB050465, INCB39110
Intervention Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
Intervention Type
Drug
Intervention Name(s)
parsaclisib + ruxolitinib
Other Intervention Name(s)
INCB050465, INCB018424
Intervention Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
Intervention Type
Drug
Intervention Name(s)
parsaclisib + ibrutinib
Other Intervention Name(s)
INCB050465
Intervention Description
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Description
Number of participants with treatment-related AEs
Time Frame
Through study completion, an average of 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib. Currently tolerating treatment in the parent Protocol. Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator. Has at least stable disease, as determined by the investigator. Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements. Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol. Willingness to avoid pregnancy or fathering children Ability to comprehend and willingness to sign an ICF Exclusion Criteria: Has been permanently discontinued from study treatment in the parent Protocol for any reason. Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study. Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol. Pregnant or breastfeeding women.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Incyte Corporation Call Center (US)
Phone
1.855.463.3463
Email
medinfo@incyte.com
First Name & Middle Initial & Last Name or Official Title & Degree
Incyte Corporation Call Center (ex-US)
Phone
+800 00027423
Email
eumedinfo@incyte.com
Facility Information:
Facility Name
Uab Comprehensive Cancer Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Alabama At Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Name
Mayo Clinic Rochester
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of Arizona Cancer Center-Out Pt.
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
City of Hope National Medical Center
City
Duarte
State/Province
California
ZIP/Postal Code
31010
Country
United States
Individual Site Status
Completed
Facility Name
California Cancer Associates For Research and Excellence
City
Fresno
State/Province
California
ZIP/Postal Code
93720
Country
United States
Individual Site Status
Completed
Facility Name
Innovative Clinical Research Institute
City
Long Beach
State/Province
California
ZIP/Postal Code
90805
Country
United States
Individual Site Status
Recruiting
Facility Name
Rocky Mountain Cancer Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Individual Site Status
Recruiting
Facility Name
Rush University Medical Center-Consultants in Hematology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Kansas Hospital Authority
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
Rcca Md, Llc
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Individual Site Status
Completed
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Michigan Cancer Center
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
Hattiesburg Clinic Hematology
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Individual Site Status
Recruiting
Facility Name
Saint Luke'S Hospital of Kansas City
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Individual Site Status
Recruiting
Facility Name
Hca Midwest Health-Research Medical Center
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
66211
Country
United States
Individual Site Status
Recruiting
Facility Name
Comprehensive Cancer Centers of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89169
Country
United States
Individual Site Status
Recruiting
Facility Name
Roswell Park Cancer Institute
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University Hospitals Case Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Completed
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Knight Cancer Institute At Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Name
Baylor Scott White Univeristy Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Washington-Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109-4405
Country
United States
Individual Site Status
Recruiting
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
01090
Country
Austria
Individual Site Status
Not yet recruiting
Facility Name
Cliniques Universitaires Ucl Saint-Luc
City
Brussels
ZIP/Postal Code
01200
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
09000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Universitaire Ziekenhuis Leuven - Gasthuisberg
City
Leuven
ZIP/Postal Code
03000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
University Hospital Hradec Kralove
City
Hradec Králové
ZIP/Postal Code
50005
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Name
Univerzita Karlova V Praze 1. Lekarska Fakulta
City
Prague 2
ZIP/Postal Code
128 00
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Name
University Hospital Kralovkse Vinohrady
City
Praha 10
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Name
Fakultni Nemocnice V Motole
City
Praha 5
ZIP/Postal Code
15000
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Name
The Finsen Centre National Hospital
City
Copenhagen
ZIP/Postal Code
02100
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Sjaellands Universitets Hospital Roskilde
City
Roskilde
ZIP/Postal Code
04000
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Aarhus University Hospital
City
Århus N
ZIP/Postal Code
08200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Name
Centre Antoine Lacassagne
City
Nice
ZIP/Postal Code
06189
Country
France
Individual Site Status
Recruiting
Facility Name
Ap-Hp Groupe Hospitalier Saint-Louis Lariboisiere Fernand-Widal Site Saint Louis (Paris)
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitaire Pitie-Salpetriere
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Recruiting
Facility Name
Centre Hospitalier Universitaire de Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Chru Hopitaux de Tours Hospital Bretonneau
City
Tours
ZIP/Postal Code
37000
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Petz Aladar County Teaching Hospital
City
Gyor
ZIP/Postal Code
09024
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Hadassah Hebrew University Medical Center Ein Karem Hadassah
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Recruiting
Facility Name
Rabin Medical Center - Beilinson Hospital
City
Petach Tikva
ZIP/Postal Code
49100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Sheba Medical Center
City
Tel Hashomer
ZIP/Postal Code
5265601
Country
Israel
Individual Site Status
Not yet recruiting
Facility Name
University of Bologna Institute of Haematology L E A Seragnoli
City
Bologna
ZIP/Postal Code
40126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Lstituto Di Ematologia Lorenzo Ea.Seragnoli Universita Degli Studi Di Bologna - Policlinico S. Or
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Azienda Ospedaliero-Universitaria Careggi (Aouc)
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori
City
Meldola (fc)
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Fondazione Irccs Ca Granda Ospedale Maggiore
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
City
Milano
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
City
Milano
ZIP/Postal Code
22162
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Universita Di Napoli Federico Ii
City
Naples
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara
City
Novara
ZIP/Postal Code
28100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
City
Palermo
ZIP/Postal Code
90146
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Azienda Ospedaliero Universitaria Pisana
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale Santa Maria Delle Croci
City
Ravenna
ZIP/Postal Code
48121
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale Sant. Eugenio
City
Roma
ZIP/Postal Code
00144
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Juntendo University Hospital
City
Bunkyo-ku
ZIP/Postal Code
113-8431
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
National Cancer Center Hospital
City
Chuo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Kansai Medical University Hospital
City
Hirakata
ZIP/Postal Code
573-1191
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Tokai University Hospital
City
Isehara
ZIP/Postal Code
259-1193
Country
Japan
Individual Site Status
Recruiting
Facility Name
Kobe City Medical Center General Hospital
City
Kobe
ZIP/Postal Code
650-0047
Country
Japan
Individual Site Status
Recruiting
Facility Name
University Hospital Kyoto Prefectural University of Medicine
City
Kyoto
ZIP/Postal Code
602-8566
Country
Japan
Individual Site Status
Recruiting
Facility Name
Nho Matsumoto Medical Center
City
Matsumoto-shi
ZIP/Postal Code
399-8701
Country
Japan
Individual Site Status
Recruiting
Facility Name
Miyagi Cancer Center
City
Miyagi
ZIP/Postal Code
981-1293
Country
Japan
Individual Site Status
Recruiting
Facility Name
Jrc Aichi Medical Center Nagoya Daini Hospital
City
Nagoya
ZIP/Postal Code
466-8650
Country
Japan
Individual Site Status
Recruiting
Facility Name
Niigata Cancer Center Hospital
City
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Osaka Metropolitan University Hospital
City
Osaka
ZIP/Postal Code
545-8585
Country
Japan
Individual Site Status
Recruiting
Facility Name
Hokuyukai Sapporo Hokuyu Hospital
City
Sapporo
ZIP/Postal Code
003-0006
Country
Japan
Individual Site Status
Recruiting
Facility Name
National Hospital Org. Hokkaido Cancer Center
City
Sapporo
ZIP/Postal Code
003-0804
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Tohoku University Hospital
City
Sendai-shi
ZIP/Postal Code
980-8574
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tokyo Medical University Hospital
City
Shinjuku
ZIP/Postal Code
160-0023
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tenri Hospital
City
Tenri
ZIP/Postal Code
632-8552
Country
Japan
Individual Site Status
Recruiting
Facility Name
Nippon Medical School Hospital
City
Tokyo
ZIP/Postal Code
113-8603
Country
Japan
Individual Site Status
Recruiting
Facility Name
Yokohama Municipal Citizens Hospital
City
Yokohama
ZIP/Postal Code
221-0855
Country
Japan
Individual Site Status
Recruiting
Facility Name
University of Fukui Hospital
City
Yoshida-gun
ZIP/Postal Code
910-1193
Country
Japan
Individual Site Status
Recruiting
Facility Name
The Catholic University of Korea Seoul St. Mary'S Hospital
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Name
Haukeland University Hospital
City
Bergen
ZIP/Postal Code
05021
Country
Norway
Individual Site Status
Not yet recruiting
Facility Name
Sp Zoz Szpital Uniwersytecki
City
Kracow
ZIP/Postal Code
31-501
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Wwcoit Im. M. Kopernika W Lodzi
City
Lodz
ZIP/Postal Code
93-513
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
City
Nowy Sacz
ZIP/Postal Code
33-300
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 1
City
Wroclaw
ZIP/Postal Code
20-081
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Hospital General Unviersitario de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Ico Hospital Germans Trias I Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Clinic Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Clinic I Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Gregorio Maranon
City
Madrid
ZIP/Postal Code
28009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Fundacin Jimnez Daz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario Hm Sanchinarro
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario Quironsalud Madrid
City
Pozuelo de Alarcon
ZIP/Postal Code
28233
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen Del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Karolinska University Hospital Solna
City
Stockholm
ZIP/Postal Code
171 76
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Name
Istanbul Medipol Universitesi Ibagcilar Medipol Mega Universitesi Hastanesi
City
Istanbul
ZIP/Postal Code
34214
Country
Turkey
Individual Site Status
Not yet recruiting
Facility Name
Ege University Hospital
City
Izmir
ZIP/Postal Code
35040
Country
Turkey
Individual Site Status
Not yet recruiting
Facility Name
Birmingham Heartlands Hospital
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD Sharing Time Frame
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD Sharing Access Criteria
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
IPD Sharing URL
https://www.incyte.com/our-company/compliance-and-transparency

Learn more about this trial

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

We'll reach out to this number within 24 hrs